title: PET studies in drug development: Methodological considerations.
abstract: Positron emission tomography (PET), as an in vivo pharmacological imaging tool in experimental medicine, is playing an increasing role in drug development. There are two areas where PET is particularly useful in this respect, namely biodistribution and drug occupancy studies. Radiotracer design, the properties of the molecular targets which can be studied and the quantitative estimation of pharmacological endpoints will be discussed in relation to these applications, with particular reference to studies in brain.:
authors: Translational Medicine and Genetics, GlaxoSmithKline, 891-995 Greenford Road, Greenford, Middlesex, UK UB6 7HE. Electronic address:vincent.j.cunningham@gsk.com.
authors: Vincent J
authors: VJ
authors: Cunningham
authors: Translational Medicine and Genetics, GlaxoSmithKline, ACCI, Addenbrookes Hospital, Hills Road, Cambridge, UK CB2 2GG.
authors: Christine A
authors: CA
authors: Parker
authors: Translational Medicine and Genetics, GlaxoSmithKline, ACCI, Addenbrookes Hospital, Hills Road, Cambridge, UK CB2 2GG.
authors: Eugenii A
authors: EA
authors: Rabiner
authors: Translational Medicine and Genetics, GlaxoSmithKline, ACCI, Addenbrookes Hospital, Hills Road, Cambridge, UK CB2 2GG.
authors: Antony D
authors: AD
authors: Gee
authors: Translational Medicine and Genetics, GlaxoSmithKline, 891-995 Greenford Road, Greenford, Middlesex, UK UB6 7HE.
authors: Roger N
authors: RN
authors: Gunn